UVB-induced skin autoinflammation due to NLRP1 mutation and its inhibition by anti-IL-1b antibody
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA721946 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR14238172_1.fastq.gz | Fastqsanger.gz | |||
| SRR14238172_2.fastq.gz | Fastqsanger.gz | |||
| SRR14238173_1.fastq.gz | Fastqsanger.gz | |||
| SRR14238173_2.fastq.gz | Fastqsanger.gz | |||
| SRR14238174_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 36 |
Similar Datasets
Project description:To analyze the pathogenic mechanism of the autoinflammatory skin syndromes caused by an NLRP1 mutation, we sought to generate Nlrp1b mutation knock-in mice mice as a mouse model of cutaneous autoinflammatory lesions due to NLRP1 mutants, and examine the expression of proteins, such as cytokines, and the mRNA expression profile, including inflammasome-related genes in the model lesions.
2022-06-14 | GSE172065 | GEO
Project description:In humans, microbial nucleic acid recognition serves as the major stimulus to an antiviral response, implying a requirement for cellular mechanisms to limit misrepresentation of self nucleic acids as non-self and the subsequent induction of type I interferon-mediated autoinflammation. This RNA-seq study was done on individuals with upregulated type I interferon signaling autoinflammatory disease.
2018-02-22 | E-MTAB-5735 | biostudies-arrayexpress
Project description:Autoinflammation with enhanced type I interferon signaling due to DNASE2 mutations
| PRJEB20731 | ENA
Project description:The danger signals that activate the NLRP1 inflammasome have yet to be firmly established. NLRP1 undergoes autoproteolysis to generate N-terminal (NT) and C-terminal (CT) fragment, which importantly, is a necessary step for its check-point regulation by the DPP9 ternary complex and the mechanistic activation of NLRP1 through functional degradation. Here, we report an added layer of regulatory complexity to NLRP1 activity, in the form of a repressive interaction that NLRP1 forms with the oxidized, but not reduced, form of thioredoxin-1 (TRX1). Loss of TRX1 destabilizes the NT fragment of NLRP1 and promotes enhanced inflammasome activation. The TRX1 interaction occurs through the NACHT-LRR of NLRP1 and requires nucleotide binding in its ATPase domain. In addition, we found that several patient-derived and ATPase-inactivating mutations in the NACHT-LRR region hyperactive the inflammasome by destabilize protein folding and are also shown to abrogate TRX1 binding. Thus, NLRP1 appears to detect intracellular reductive stress through a decrease in the fraction of intracellular oxidized TRX1, which enhances protein disorder, leading to inflammasome signaling. These findings link the cellular redox environment to NLRP1-mediated innate immunity.
2022-11-04 | GSE215035 | GEO
Project description:The danger signals that activate the NLRP1 inflammasome have yet to be firmly established. NLRP1 undergoes autoproteolysis to generate N-terminal (NT) and C-terminal (CT) fragment, which importantly, is a necessary step for its check-point regulation by the DPP9 ternary complex and the mechanistic activation of NLRP1 through functional degradation. Here, we report an added layer of regulatory complexity to NLRP1 activity, in the form of a repressive interaction that NLRP1 forms with the oxidized, but not reduced, form of thioredoxin-1 (TRX1). Loss of TRX1 destabilizes the NT fragment of NLRP1 and promotes enhanced inflammasome activation. The TRX1 interaction occurs through the NACHT-LRR of NLRP1 and requires nucleotide binding in its ATPase domain. In addition, we found that several patient-derived and ATPase-inactivating mutations in the NACHT-LRR region hyperactive the inflammasome by destabilize protein folding and are also shown to abrogate TRX1 binding. Thus, NLRP1 appears to detect intracellular reductive stress through a decrease in the fraction of intracellular oxidized TRX1, which enhances protein disorder, leading to inflammasome signaling. These findings link the cellular redox environment to NLRP1-mediated innate immunity.
2022-11-04 | GSE215034 | GEO
Project description:To find cellular protein binding partners of the NLRP1 inflammasome, FLAG-tagged full length NLRP1 (or a GFP-FLAG protein control) was ectopically expressed in HEK 293T cells and affinity purified from cell lysates (Note: the NLRP1-FLAG-containing lysate samples were affinity purified in the presence or absence of excess proline) before proteins were reduced, alkylated, and trypsinized before TMT labelling and pooling of the differentially tested lysates to give three conditions (1. NLRP1-FLAG; 2. GFP-FLAG; 3. NLRP1-FLAG+proline) in duplicate. These data represent the results following sample and data processing.
2022-11-04 | PXD037391 | Pride
Project description:Diamond-Blackfan Anemia Syndrome (DBAS) is characterized by impaired erythropoiesis due to dysfunctional ribosome biogenesis and aberrant cellular signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome modulates erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis in Diamond-Blackfan anemia syndrome (DBAS) by inhibiting NLRP1 inflammasome activation. Specifically, nilotinib enhances erythroid differentiation in K562 cells through suppression of the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 protein levels and upregulation of key erythroid genes involved in iron acquisition, hemoglobin synthesis, and erythrocyte structure. These effects were validated in human CD34+ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, along with other TKIs (imatinib, dasatinib, and bosutinib), promoted erythropoiesis at the expense of myelopoiesis and reduced caspase-1 activity. Importantly, in RPS19-deficient zebrafish and human models and HSPCs from patients with DBAS, nilotinib, imatinib and dasatinib rescued defective erythroid differentiation and restored hemoglobin levels. These findings highlight the potential of TKIs to address the erythroid defects observed in ribosomopathies like DBAS. Given the limited treatment options available for DBAS and other congenital anemias, our study provides compelling evidence for repurposing TKIs as a novel therapeutic strategy to alleviate pathological NLRP1 activation and improve erythropoiesis. This work opens new avenues for managing ribosome-related disorders and advancing personalized medicine approaches for hematopoietic diseases.
2025-09-01 | GSE300483 | GEO
Project description:Psoriasis is a common inflammatory disease that affects mainly the skin. The pro-inflammatory cytokines interleukin(IL)-1β and IL-36γ are involved in its pathogenesis. However, the molecular and cellular mechanisms underlying the regulation of these pathways in psoriasis are incompletely understood. IL-1β activity is produced downstream of a group of protein complexes termed inflammasomes, which are primarily expressed by immune cells. To address the function of the NLRP1 inflammasome in epidermal keratinocytes, we activated NLRP1 pharmacologically in human skin equivalents (SEs), an organotypic three-dimensional skin model. In the epidermis of these SEs, IL-1β secretion induced a histological phenotype that resembles psoriasis and is associated with a characteristic pro-inflammatory gene expression signature, including the induction of IL-36γ expression and secretion. Whereas expression of IL-36γ is induced by IL-1β, IL-36γ secretion occurs downstream of NLRP1 activation through gasdermin D pores. Most importantly, we detected inflammasome activation in suprabasal keratinocytes in lesional psoriasis. Release of endogenous double stranded (ds) RNA to the cytoplasm is associated with cellular perturbations in several inflammatory conditions, including psoriasis. In keratinocytes in monoculture, we identified short self-derived dsRNA as a novel activator of the NLRP1 inflammasome. These data suggest a critical role of keratinocytes in the pathogenesis of psoriasis through activation of the NLRP1 inflammasome. Furthermore, NLRP1-activated SEs represent a novel in vitro model for this condition, based on human primary skin cells. Most importantly, pharmacological targeting and inhibition of NLRP1 appears as a novel treatment option for psoriasis.
2025-09-23 | GSE282206 | GEO
Project description:This study comprehensively investigates the photoprotective effects of aloin against UVB-induced damage in HaCaT cells, elucidating its antioxidant capacity and its role in preventing cellular apoptosis. The proteomic effect of 50 μg/mL aloin on HaCaT cell damage induced by UVB was evaluated through comparative protein expression. Compared to control cells, UVB irradiation significantly altered protein expression in HaCaT cells, with 64 proteins upregulated and 236 proteins downregulated. In cells treated with both UVB and aloin, 79 proteins were upregulated and 84 proteins were downregulated compared to the UVB-only group. Proteomic analysis showed that aloin modulated the expression of proteins involved in critical signaling pathways, including PI3K-Akt, p53, TGF-β and pathways in cancer, promoting cell survival. Aloin upregulated proteins associated with cell cycle regula-tion and antioxidant responses, such as CCND3, GSTM4, GNA12, SKIL, YWHAZ, and PKN3 while downregulating pro-apoptotic protein FOXO3.
2025-08-04 | PXD060808 | Pride
Project description:Immune response genes are disproportionately polymorphic in humans and mice, with heterogeneity amongst loci driving strain specific host defense responses. The inadvertent retention of polymorphic loci can confound results, lead to false conclusions, and delay scientific progress. By combining RNAseq and variant calling analyses, we identify a substantial region of 129S genome, including the highly polymorphic Nlrp1 locus proximal to Nlrp3, in one of the most commonly used mouse models of NLRP3 deficiency. We show that 129S NLRP1 can be tolerated at higher expression levels at steady-state, however this sensitizes Nlrp3-/- mice to NLRP1 inflammasome activation. Furthermore, the presence of 129S genome leads to altered gene and protein regulation across multiple cell-types, including of the key tissue-resident macrophage marker, TIM4. In order to resolve NLRP3 dependent phenotypes we validate a conditional Nlrp3 allele enabling temporal and cell-type specific control of NLRP3 deletion. Our study provides an accessible strategy to identify functionally relevant SNPs and assess genomic contamination in transgenic mice, to allow for unambiguous attribution of phenotypes to the target gene.
2024-01-23 | E-MTAB-13601 | biostudies-arrayexpress